Alberta Health Minister Adriana LaGrange has signed a deal with her federal counterpart to expand access to medication for people with rare diseases.
LaGrange joined federal Health Minister Mark Holland in Edmonton to announce millions in spending on both emerging and proven drugs, as well as on diagnostics and screening.
The drugs include Poteligeo for treating Sézary syndrome, Oxlumo for hyperoxaluria type 1 and Epkinly for large B-cell lymphoma.
Get weekly health news
LaGrange says the move will help support Albertans living with rare diseases and open the door to potentially life-changing treatments.
Holland says the deal is a step toward building a stronger public health system for Albertans and aims to give Albertans with rare diseases the “best health outcomes possible.”
Alberta is the third province behind B.C. and Newfoundland and Labrador to sign onto a federal deal under the National Strategy for Drugs for Rare Diseases.
- Nova Scotia aims to reduce mammogram wait times, enhance women’s health care
- Anthrax outbreak kills more than 50 animals, infects 12 people in Zambia
- Childhood Cancer Canada calls for $15M from feds as demand rises
- ‘E-dirt bikes are not toys’: E.R. doc fears more injuries after 2 kids hit in Edmonton
-
![]()
3 children with rare, fatal disease access treatment to prolong their lives -
![]()
Alberta family advocates for ultra-rare gene condition on Rare Disease Day -
![]()
Alberta family dealing with rare disease while still reeling from dad’s murder -
![]()
Edmonton resident living with ‘one-in-a-million’ lung condition. -
![]()
Alberta doctor becomes a rare disease patient, shares lessons he learned in hospital -
![]()
Alberta siblings with rare, terminal disease finally have hope for a treatment
Comments
Want to discuss? Please read our Commenting Policy first.